INGN 241 in phase II clinical trial

Article

Source: www.biotechnologyhealthcare.com Austin, Texas ? Introgen Therapies announced initiation of a Phase II clinical trial of INGN 241 in patients with metastatic melanoma.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.